- Global Pharma News & Resources

Swedish innovation help to accelerate diagnosis of leukemia for children

Swedish innovation help to accelerate diagnosis of leukemia for children

Swedish Qlucore - a leader in precision diagnostics for the analysis of cancer - has played an important role in the Swedish-Danish collaboration iCOPE, which aims, among other things, to improve the treatment of children affected by acute leukemia. With diagnoses increasing by 6-10 percent a year in Europe, acute leukemia in children still experiences high mortality and treatment-related complications.

The iCOPE collaboration, which is financed by EU grants, has been operating for three years, and spans the Öresund region. It includes patients and researchers from Skåne region, Lund University, Rigshospitalet and the Technical University of Denmark.

"Here, our proprietary software is very useful, both during the project and now also as a permanent solution. It enables easier assessment of a cancer’s subgroup by analyzing large amounts of data. This is something that can be labor-intensive and cumbersome with traditional methods,” says Carl-Johan Ivarsson, Qlucore's CEO.

With the help of the Qlucore Insights software, iCOPE aims to improve the so-called precision diagnostics in acute leukemia.

"We chose Qlucore's software because it is automated, user-friendly and has a perfect visual presentation - almost like 3D. This is good for doctors with limited understanding of childhood leukemia, as well as parents as it is easy to print a result and show them," says Kjeld Schmiegelow (Professor and Senior Hospital Physician).

With the help of precision diagnostics based on so-called RNA sequencing, iCOPE can improve care for children affected by acute childhood leukemia.

"The best thing is that we can implement RNA sequencing in clinical diagnostics in a simple and safe way and that the software helps us in this important work. If we hadn't had access to Qlucore's software, it would have required a lot of work by specialized bioinformaticians, researchers and doctors, which would have been both costly and time-consuming," says Mette Klarskov Andersen, doctor at Rikshospitalet in Copenhagen.

She continues: “We have had many software solutions presented to us in the past, but none of these have met our desires or been designed to suit our needs. This software has impressed us and makes it possible to design the right treatment method and eventually move towards personalized care and medication”.

Certified Advisor

FNCA Sweden AB


Editor Details

Last Updated: 13-Oct-2022